

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 217/04, A61K 31/47, C07D 217/06, 217/02		A1	(11) International Publication Number: WO 98/41507
			(43) International Publication Date: 24 September 1998 (24.09.98)
(21) International Application Number: PCT/GB98/00781		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 16 March 1998 (16.03.98)			
(30) Priority Data: 9705620.4 18 March 1997 (18.03.97) GB 9726660.5 17 December 1997 (17.12.97) GB			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HARLING, John, David [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). ORLEK, Barry/Sidney [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). THOMPSON, Mervyn [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).		Published With international search report.	
(74) Agent: WEST, Vivien; SmithKline Beecham PLC, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			

(54) Title: ANTI-CONVULSANT ISOQUINOLYL-BENZAMIDE DERIVATIVES

(57) Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof, where R^1 is hydrogen, C_{1-6} alkyl (optionally substituted by hydroxy or C_{1-4} alkoxy), C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} alkylCO-, formyl, CF_3 CO- or C_{1-6} alkylSO₂-; R^2 is hydrogen or up to three substituents selected from halogen, NO₂, CN, N₃, CF_3 O-, CF_3 S-, CF_3 CO-, trifluoromethyldiaziriny, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} perfluoroalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl-, C_{1-6} alkylO-, C_{1-6} alkylCO-, C_{3-6} cycloalkylO-, C_{3-6} cycloalkylCO-, C_{3-6} cycloalkyl- C_{1-4} alkylO-, C_{3-6} cycloalkyl- C_{1-4} alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl- C_{1-4} alkyl-, C_{1-6} alkylS-, C_{1-6} alkylSO₂-, $(C_{1-4}$ alkyl)₂NSO₂-, $(C_{1-4}$ alkyl)NHSO₂-, $(C_{1-4}$ alkyl)₂NCO-, $(C_{1-4}$ alkyl)NHCO- or CONH₂; or -NR⁵R⁶ where R^5 is hydrogen or C_{1-4} alkyl, and R^6 is hydrogen, C_{1-4} alkyl, formyl, -CO₂ C_{1-4} alkyl or -COC₁₋₄alkyl; or two R^2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by -OH or =O; and the two R^3 groups and the two R^4 groups are each independently hydrogen or C_{1-6} alkyl or the two R^3 groups and/or the two R^4 groups together form a C_{3-6} spiroalkyl group provided that at least one R^3 and R^4 group is not hydrogen, are useful in the treatment and prophylaxis of epilepsy and other disorders.

